Immunity and inflammation in status epilepticus and its sequelae: Possibilities for therapeutic application

Expert Review of Neurotherapeutics

Volumn 15, Issue 9, 2015, Pages 1081-1092

  Vezzani, Annamaria ^a   Dingledine, Raymond ^b   Rossetti, Andrea O ^c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

animal models; anti inflammatory treatments; bloodbrain barrier; comorbidities; COX 2; cytokines; neurodegeneration; outcome; prognosis; refractory status epilepticus; seizures

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE;

ANTICONVULSANT THERAPY; DISEASE CLASSIFICATION; ELECTROCONVULSIVE THERAPY; ENCEPHALITIS; EPILEPTIC STATE; HUMAN; IMMUNITY; INCIDENCE; NEUROPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; REVIEW; SEIZURE SUSCEPTIBILITY; SEIZURE THRESHOLD; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE STIMULATION; ANIMAL; INFLAMMATION; PATHOPHYSIOLOGY; SEIZURE;

ANIMALS; ANTICONVULSANTS; BENZODIAZEPINES; HUMANS; INFLAMMATION; SEIZURES; STATUS EPILEPTICUS;

EID: 84940655834     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1079130     Document Type: Review

References (152)

1. Lowenstein DH. Status epilepticus: An overview of the clinical problem. Epilepsia 1999;40(Suppl 1):S3-8
2. Knake S, Rosenow F, Vescovi M, et al. Incidence of status epilepticus in adults in Germany: A prospective, population-based study. Epilepsia 2001;42(6):714-18
3. DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996;46(4): 1029-35
4. Dham BS, Hunter K, Rincon F. The epidemiology of status epilepticus in the United States. Neurocrit Care 2014;20(3): 476-83
5. Holtkamp M. The anaesthetic and intensive care of status epilepticus. Curr Opin Neurol 2007;20(2):188-93
6. Mayer SA, Claassen J, Lokin J, et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002;59(2):205-10
7. Kellinghaus C, Stogbauer F. Treatment of status epilepticus in a large community hospital. Epilepsy Behav 2012;23(3):235-40
8. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: A prospective observational study. Epilepsia 2010;51(2): 251-6
9. Rossetti AO, Milligan TA, Vulliemoz S, et al. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care 2011;14(1):4-10
10. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: A critical review of available therapies and a clinical treatment protocol. Brain 2011;134(Pt 10): 2802-18
11. Trinka E, Cock H, Hesdorffer DC, et al. A definition and classification of status epilepticus-Report of the task force on classification of status epilepticus. Epilepsia 2015. [Epub ahead of print]
12. Shorvon S. The classification of status epilepticus. Epileptic Disord 2005;7(1):1-3
13. Rossetti AO, Hurwitz S, Logroscino G, Bromfield EB. Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry 2006;77(5): 611-15
14. Alvarez V, Westover MB, Drislane FW, et al. Evaluation of a clinical tool for early etiology identification in status epilepticus. Epilepsia 2014;55(12):2059-68
15. Spatola M, Novy J, Du Pasquier R, et al. Status epilepticus of inflammatory etiology: A cohort study. Neurology 2015;85(5): 464-70
16. Amare A, Zenebe G, Hammack J, Davey G. Status epilepticus: clinical presentation, cause, outcome, and predictors of death in 119 Ethiopian patients. Epilepsia 2008; 49(4):600-7
17. Holzer FJ, Seeck M, Korff CM. Autoimmunity and inflammation in status epilepticus: from concepts to therapies. Expert Rev Neurother 2014;14(10): 1181-202
18. Holzer FJ, Rossetti AO, Heritier-Barras AC, et al. Antibody-mediated status epilepticus: A retrospective multicenter survey. Eur Neurol 2012;68(5):310-17
19. Holtkamp M, Othman J, Buchheim K, et al. A "malignant" variant of status epilepticus. Arch Neurol 2005;62(9): 1428-31
20. Wilder-Smith EP, Lim EC, Teoh HL, et al. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singapore 2005; 34(7):417-20
21. Nabbout R, Vezzani A, Dulac O, Chiron C. Acute encephalopathy with inflammation-mediated status epilepticus. Lancet Neurol 2011;10(1):99-108
22. van Baalen A, Hausler M, Boor R, et al. Febrile infection-related epilepsy syndrome (FIRES): A nonencephalitic encephalopathy in childhood. Epilepsia 2010;51(7):1323-8
23. Khawaja AM, DeWolfe JL, Miller DW, Szaflarski JP. New-onset refractory status epilepticus (NORSE)-The potential role for immunotherapy. Epilepsy Behav 2015;47:17-23
24. Logroscino G, Hesdorffer DC, Cascino GD, et al. Long-term mortality after a first episode of status epilepticus. Neurology 2002;58(4):537-41
25. Sutter R, Kaplan PW, Ruegg S. Outcome predictors for status epilepticus-what really counts. Nat Rev Neurol 2013;9(9):525-34
26. Hocker SE, Britton JW, Mandrekar JN, et al. Predictors of outcome in refractory status epilepticus. JAMA Neurol 2013; 70(1):72-7
27. Aminoff MJ. Do nonconvulsive seizures damage the brain?-No. Arch Neurol 1998; 55(1):119-20
28. Young GB, Jordan KG. Do nonconvulsive seizures damage the brain?-Yes. Arch Neurol 1998;55(1):117-19
29. Fernandez-Torre JL, Figols J, Martinez-Martinez M, et al. Localisation-related nonconvulsive status epilepticus: Further evidence of permanent cerebral damage. J Neurol 2006;253(3): 392-5
30. Salmenpera T, Kalviainen R, Partanen K, et al. MRI volumetry of the hippocampus, amygdala, entorhinal cortex, and perirhinal cortex after status epilepticus. Epilepsy Res 2000;40(2-3):155-70
31. Adachi N, Kanemoto K, Muramatsu R, et al. Intellectual prognosis of status epilepticus in adult epilepsy patients: Analysis with Wechsler Adult Intelligence Scale-revised. Epilepsia 2005;46(9):1502-9
32. Meldrum BS, Horton RW. Physiology of status epilepticus in primates. Arch Neurol 1973;28(1):1-9
33. Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol 2011;10(10):922-30
34. Capovilla G, Beccaria F, Beghi E, et al. Treatment of convulsive status epilepticus in childhood: recommendations of the Italian League Against Epilepsy. Epilepsia 2013; 54(Suppl 7):23-34
35. Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 2010;17(3):348-55
36. Rossetti AO, Alvarez V, Januel JM, Burnand B. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol 2013;260(2): 421-8
37. Jaques L, Rossetti AO. Newer antiepileptic drugs in the treatment of status epilepticus: impact on prognosis. Epilepsy Behav 2012; 24(1):70-3
38. Sutter R, Marsch S, Fuhr P, et al. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology 2014;82(8):656-64
39. Marchi NA, Novy J, Faouzi M, et al. Status epilepticus: impact of therapeutic coma on outcome. Crit Care Med 2015;43(5):1003-9
40. Rossetti AO, Bleck TP. What's new in status epilepticus? Intensive Care Med 2014; 40(9):1359-62
41. Synowiec AS, Singh DS, Yenugadhati V, et al. Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res 2013;105(1-2):183-8
42. Gaspard N, Foreman B, Judd LM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: A retrospective multicenter study. Epilepsia 2013;54(8): 1498-503
43. Pruss H, Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res 2008;82(2-3): 219-22
44. Mazarati AM, Wasterlain CG. N-methyl-Dasparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett 1999; 265(3):187-90
45. Caraballo RH, Flesler S, Armeno M, et al. Ketogenic diet in pediatric patients with refractory focal status epilepticus. Epilepsy Res 2014;108(10):1912-16
46. Thakur KT, Probasco JC, Hocker SE, et al. Ketogenic diet for adults in super-refractory status epilepticus. Neurology 2014;82(8): 665-70
47. Irani SR, Bien CG, Lang B. Autoimmune epilepsies. Curr Opin Neurol 2011;24(2): 146-53
48. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurol 2013;12(2):157-65
49. Bien CG, Schramm J. Treatment of Rasmussen encephalitis half a century after its initial description: promising prospects and a dilemma. Epilepsy Res 2009;86(2-3): 101-12
50. Miskin C, Hasbani DM. Status epilepticus: immunologic and inflammatory mechanisms. Semin Pediatr Neurol 2014; 21(3):221-5
51. Vezzani A, Balosso S, Aronica E, Ravizza T. Basic mechanisms of status epilepticus due to infection and inflammation. Epilepsia 2009;50(Suppl 12):56-7
52. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol 2011;7(1):31-40
53. Lewis DV, Shinnar S, Hesdorffer DC, et al. Hippocampal sclerosis after febrile status epilepticus: The FEBSTAT study. Ann Neurol 2014;75(2):178-85
54. Nixon J, Bateman D, Moss T. An MRI and neuropathological study of a case of fatal status epilepticus. Seizure 2001;10(8): 588-91
55. Corsellis JA, Bruton CJ. Neuropathology of status epilepticus in humans. Adv Neurol 1983;34:129-39
56. Fujikawa DG, Itabashi HH, Wu A, Shinmei SS. Status epilepticus-induced neuronal loss in humans without systemic complications or epilepsy. Epilepsia 2000; 41(8):981-91
57. Choi J, Nordli DR Jr, Alden TD, et al. Cellular injury and neuroinflammation in children with chronic intractable epilepsy. J Neuroinflammation 2009;6:38
58. Aronica E, Ravizza T, Zurolo E, Vezzani A. Astrocyte immune response in epilepsy. Glia 2012;60(8):1258-68
59. Ravizza T, Gagliardi B, Noe F, et al. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 2008;29(1):142-60
60. Zattoni M, Mura ML, Deprez F, et al. Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy. J Neurosci 2011;31(11):4037-50
61. Iori V, Maroso M, Rizzi M, et al. Receptor for Advanced Glycation Endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures. Neurobiol Dis 2013;58:102-14
62. Ashhab MU, Omran A, Kong H, et al. Expressions of tumor necrosis factor alpha and microRNA-155 in immature rat model of status epilepticus and children with mesial temporal lobe epilepsy. J Mol Neurosci 2013;51(3):950-8
63. Maroso M, Balosso S, Ravizza T, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010;16(4):413-19
64. Aronica E, Crino PB. Inflammation in epilepsy: clinical observations. Epilepsia 2011;52(Suppl 3):26-32
65. Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012;135(Pt 5): 1622-38
66. Pardo CA, Vining EP, Guo L, et al. The pathology of Rasmussen syndrome: stages of cortical involvement and neuropathological studies in 45 hemispherectomies. Epilepsia 2004;45(5):516-26
67. Liu ZS, Wang QW, Wang FL, Yang LZ. Serum cytokine levels are altered in patients with West syndrome. Brain Dev 2001; 23(7):548-51
68. Liimatainen S, Lehtimaki K, Palmio J, et al. Immunological perspectives of temporal lobe seizures. J Neuroimmunol 2013; 263(1-2):1-7
69. Choi J, Min HJ, Shin JS. Increased levels of HMGB1 and pro-inflammatory cytokines in children with febrile seizures. J Neuroinflammation 2011;8:135
70. van Vliet EA, da Costa Araujo S, Redeker S, et al. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007;130(2):521-34
71. Juhasz C, Buth A, Chugani DC, et al. Successful surgical treatment of an inflammatory lesion associated with new-onset refractory status epilepticus. Neurosurg Focus 2013;34(6):E5
72. Sakuma H, Tanuma N, Kuki I, et al. Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus. J Neurol Neurosurg Psychiatry 2014;86(7):820-2
73. Vezzani A, Friedman A, Dingledine RJ. The role of inflammation in epileptogenesis. Neuropharmacology 2013;69:16-24
74. Jiang J, Dingledine R. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends Pharmacol Sci 2013;34(7):413-23
75. van Vliet EA, Aronica E, Gorter JA. Blood-brain barrier dysfunction, seizures and epilepsy. Semin Cell Dev Biol 2015;38: 26-34
76. Vezzani A, Maroso M, Balosso S, et al. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun 2011; 25(7):1281-9
77. Rojas A, Jiang J, Ganesh T, et al. Cyclooxygenase-2 in epilepsy. Epilepsia 2014;55(1):17-25
78. De Simoni MG, Perego C, Ravizza T, et al. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci 2000;12(7):2623-33
79. Dhote F, Peinnequin A, Carpentier P, et al. Prolonged inflammatory gene response following soman-induced seizures in mice. Toxicology 2007;238(2-3):166-76
80. Williams AJ, Berti R, Yao C, et al. Central neuro-inflammatory gene response following soman exposure in the rat. Neurosci Lett 2003;349(3):147-50
81. Pernot F, Heinrich C, Barbier L, et al. Inflammatory changes during epileptogenesis and spontaneous seizures in a mouse model of mesiotemporal lobe epilepsy. Epilepsia 2011;52(12):2315-25
82. Rojas A, Ganesh T, Lelutiu N, et al. Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus. Neuropharmacology 2015;93: 15-27
83. Jiang J, Yang MS, Quan Y, et al. Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Neurobiol Dis 2015;76:126-36
84. Jiang J, Quan Y, Ganesh T, et al. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci USA 2013;110(9):3591-6
85. Borges K, Gearing M, McDermott DL, et al. Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model. Exp Neurol 2003; 182(1):21-34
86. Serrano GE, Lelutiu N, Rojas A, et al. Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. J Neurosci 2011;31(42):14850-60
87. Librizzi L, Noe F, Vezzani A, et al. Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage. Ann Neurol 2012;72(1): 82-90
88. Noe FM, Polascheck N, Frigerio F, et al. Pharmacological blockade of IL-1beta/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis 2013;59:183-93
89. Marchi N, Fan Q, Ghosh C, et al. Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol Dis 2009;33(2):171-81
90. Bellavance MA, Gosselin D, Yong VW, et al. Patrolling monocytes play a critical role in CX3CR1-mediated neuroprotection during excitotoxicity. Brain Struct Funct 2015;220(3):1759-76
91. Rizzi M, Perego C, Aliprandi M, et al. Glia activation and cytokine increase in rat hippocampus by kainic acid-induced status epilepticus during postnatal development. Neurobiol Dis 2003;14(3):494-503
92. Marcon J, Gagliardi B, Balosso S, et al. Age-dependent vascular changes induced by status epilepticus in rat forebrain: implications for epileptogenesis. Neurobiol Dis 2009;34(1):121-32
93. Dube C, Vezzani A, Behrens M, et al. Interleukin-1beta contributes to the generation of experimental febrile seizures. Ann Neurol 2005;57(1):152-5
94. Ravizza T, Rizzi M, Perego C, et al. Inflammatory response and glia activation in developing rat hippocampus after status epilepticus. Epilepsia 2005;46(Suppl 5): 113-17
95. Haut SR, Veliskova J, Moshe SL. Susceptibility of immature and adult brains to seizure effects. Lancet Neurol 2004;3(10): 608-17
96. Dube CM, Ravizza T, Hamamura M, et al. Epileptogenesis provoked by prolonged experimental febrile seizures: mechanisms and biomarkers. J Neurosci 2010;30(22): 7484-94
97. Choy M, Dube CM, Patterson K, et al. A novel, noninvasive, predictive epilepsy biomarker with clinical potential. J Neurosci 2014;34(26):8672-84
98. Galic MA, Riazi K, Heida JG, et al. Postnatal inflammation increases seizure susceptibility in adult rats. J Neurosci 2008; 28(27):6904-13
99. Galic MA, Riazi K, Henderson AK, et al. Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats. Neurobiol Dis 2009;36(2):343-51
100. Colciaghi F, Finardi A, Frasca A, et al. Status epilepticus-induced pathologic plasticity in a rat model of focal cortical dysplasia. Brain 2011;134(Pt 10):2828-43
101. Vezzani A, Conti M, De Luigi A, et al. Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci 1999; 19(12):5054-65
102. Aronica E, Boer K, van Vliet EA, et al. Complement activation in experimental and human temporal lobe epilepsy. Neurobiol Dis 2007;26(3):497-511
103. Pernhorst K, Herms S, Hoffmann P, et al. TLR4, ATF-3 and IL8 inflammation mediator expression correlates with seizure frequency in human epileptic brain tissue. Seizure 2013;22(8):675-8
104. Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. Cell 2010;140(6):918-34
105. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 2005;18(3):315-21
106. Craft JM, Watterson DM, Van Eldik LJ. Neuroinflammation: A potential therapeutic target. Expert Opin Ther Targets 2005;9(5): 887-900
107. Xiong ZQ, Qian W, Suzuki K, McNamara JO. Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J Neurosci 2003;23(3): 955-60
108. Ravizza T, Balosso S, Aronica E, Vezzani A. Brain inflammation and epilepsy. In: Rho JM, Sankar R, Strafstrom CE, editors. Epilepsy: mechanisms, models and translational perspectives. CRC Press, Boca Raton, FL, USA; 2010
109. Kulkarni SK, Dhir A. Cyclooxygenase in epilepsy: from perception to application. Drugs Today (Barc) 2009;45(2):135-54
110. Benson MJ, Thomas NK, Talwar S, et al. A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models. Neurobiol Dis 2015;76:87-97
111. Henshall DC, Engel T. P2X purinoceptors as a link between hyperexcitability and neuroinflammation in status epilepticus. Epilepsy Behav 2015; Epub ahead of print
112. Henshall DC, Diaz-Hernandez M, Miras-Portugal MT, Engel T. P2X receptors as targets for the treatment of status epilepticus. Front Cell Neurosci 2013;7:237
113. Schroder K, Tschopp J. The inflammasomes. Cell 2010;140(6):821-32
114. Lu B, Wang H, Andersson U, Tracey KJ. Regulation of HMGB1 release by inflammasomes. Protein Cell 2013;4(3): 163-7
115. Marchi N, Granata T, Freri E, et al. Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS One 2011;6(3):e18200
116. Sorrells SF, Caso JR, Munhoz CD, Sapolsky RM. The stressed CNS: when glucocorticoids aggravate inflammation. Neuron 2009;64(1):33-9
117. Duffy BA, Chun KP, Ma D, et al. Dexamethasone exacerbates cerebral edema and brain injury following lithium-pilocarpine induced status epilepticus. Neurobiol Dis 2014;63:229-36
118. Vezzani A, Viviani B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacol 2015;96(Pt A):70-82
119. Fourgeaud L, Boulanger LM. Role of immune molecules in the establishment and plasticity of glutamatergic synapses. Eur J Neurosci 2010;32(2):207-17
120. Carpentier PA, Palmer TD. Immune influence on adult neural stem cell regulation and function. Neuron 2009; 64(1):79-92
121. Galanopoulou AS, Moshe SL. The epileptic hypothesis: developmentally related arguments based on animal models. Epilepsia 2009;50(Suppl 7):37-42
122. Heida JG, Pittman QJ. Causal links between brain cytokines and experimental febrile convulsions in the rat. Epilepsia 2005;46(12):1906-13
123. Heida JG, Moshe SL, Pittman QJ. The role of interleukin-1beta in febrile seizures. Brain Dev 2009;31(5):388-93
124. Dube C, Richichi C, Bender RA, et al. Temporal lobe epilepsy after experimental prolonged febrile seizures: prospective analysis. Brain 2006;129(Pt 4):911-922
125. Sankar R, Auvin S, Mazarati A, Shin D. Inflammation contributes to seizure-induced hippocampal injury in the neonatal rat brain. Acta Neurol Scand 2007;115(4): 16-20
126. Somera-Molina KC, Robin B, Somera CA, et al. Glial activation links early-life seizures and long-term neurologic dysfunction: evidence using a small molecule inhibitor of proinflammatory cytokine upregulation. Epilepsia 2007;48(9):1785-800
127. Auvin S, Mazarati A, Shin D. Inflammation enhances epileptogenesis in immature rat brain. Neurobiol Dis 2010;40(1):303-10
128. Reid AY, Riazi K, Campbell Teskey G, Pittman QJ. Increased excitability and molecular changes in adult rats after a febrile seizure. Epilepsia 2013;54(4):e45-8
129. Harre EM, Galic MA, Mouihate A, et al. Neonatal inflammation produces selective behavioural deficits and alters N-methyl-Daspartate receptor subunit mRNA in the adult rat brain. Eur J Neurosci 2008;27(3): 644-53
130. Garcia-Morales I, de la Pena Mayor P, Kanner AM. Psychiatric comorbidities in epilepsy: identification and treatment. Neurologist 2008;14(6 Suppl 1):S15-25
131. Tarr AJ, McLinden KA, Kranjac D, et al. The effects of age on lipopolysaccharide-induced cognitive deficits and interleukin-1beta expression. Behav Brain Res 2011;217(2):481-5
132. Goshen I, Yirmiya R. Interleukin-1 (IL-1): A central regulator of stress responses. Front Neuroendocrinol 2009;30(1):30-45
133. Mazarati A, Maroso M, Iori V, et al. High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products. Exp Neurol 2011;232(2): 143-8
134. Smith SE, Li J, Garbett K, et al. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007;27(40):10695-702
135. Emanuele E, Boso M, Brondino N, et al. Increased serum levels of high mobility group box 1 protein in patients with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(4):681-3
136. Boso M, Emanuele E, Minoretti P, et al. Alterations of circulating endogenous secretory RAGE and S100A9 levels indicating dysfunction of the AGE-RAGE axis in autism. Neurosci Lett 2006;410(3): 169-73
137. Enstrom AM, Onore CE, Van de Water JA, Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun 2010;24(1):64-71
138. Sun J, Xie C, Liu W, et al. The effects of simvastatin on hippocampal caspase-3 and Bcl-2 expression following kainate-induced seizures in rats. Int J Mol Med 2012;30(4): 739-46
139. van Vliet EA, Holtman L, Aronica E, et al. Atorvastatin treatment during epileptogenesis in a rat model for temporal lobe epilepsy. Epilepsia 2011;52(7):1319-30
140. Xie C, Sun J, Qiao W, et al. Administration of simvastatin after kainic acid-induced status epilepticus restrains chronic temporal lobe epilepsy. PLoS One 2011;6(9):e24966
141. Sierra-Marcos A, Alvarez V, Faouzi M, et al. Statins are associated with decreased mortality risk after status epilepticus. Eur J Neurol 2015;22(2):402-5
142. Vezzani A. Anti-inflammatory drugs in epilepsy: does it impact epileptogenesis? Expert Opin Drug Saf 2015;14(4):583-92
143. Jung KH, Chu K, Lee ST, et al. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol Dis 2006;23(2):237-46
144. Polascheck N, Bankstahl M, Loscher W. The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. Exp Neurol 2010;224(1):219-33
145. Ma L, Cui XL, Wang Y, et al. Aspirin attenuates spontaneous recurrent seizures and inhibits hippocampal neuronal loss, mossy fiber sprouting and aberrant neurogenesis following pilocarpine-induced status epilepticus in rats. Brain Res 2012;1469:103-13
146. Fabene PF, Mora GN, Martinello M, et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med 2008; 14(12):1377-83
147. Chu K, Jung KH, Lee ST, et al. Erythropoietin reduces epileptogenic processes following status epilepticus. Epilepsia 2008;49(10):1723-32
148. Gao F, Liu Y, Li X, et al. Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model. Pharmacol Biochem Behav 2012;103(2):187-96
149. Wang N, Mi X, Gao B, et al. Minocycline inhibits brain inflammation and attenuates spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neuroscience 2015;287:144-56
150. Kwon YS, Pineda E, Auvin S, et al. Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain. J Neuroinflammation 2013;10:30
151. Mazzuferi M, Kumar G, van Eyll J, et al. Nrf2 defense pathway: Experimental evidence for its protective role in epilepsy. Ann Neurol 2013;74(4):560-8
152. Gouveia TL, Scorza FA, Iha HA, et al. Lovastatin decreases the synthesis of inflammatory mediators during epileptogenesis in the hippocampus of rats submitted to pilocarpine-induced epilepsy. Epilepsy Behav 2014;36:68-73